MDxHealth (NASDAQ:MDXH) Issues Earnings Results, Misses Estimates By $0.05 EPS

14 May 2026, 21:32 by Doug Wharley · The Cerbat Gem

MDxHealth (NASDAQ:MDXH – Get Free Report) issued its earnings results on Wednesday. The company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.05), FiscalAI reports. MDxHealth had a negative net margin of 31.07% and a negative return on equity of 1,078.01%. The firm had revenue of $23.90 million during the quarter, compared to analyst estimates of $30.89 million.

Here are the key takeaways from MDxHealth’s conference call:

MDxHealth will discontinue its Resolve UTI business and shut the Plano lab, citing an increasingly uncertain reimbursement environment and a recent Novitas policy reversal.
The company said Novitas is seeking up to $10.4 million in recoupments of historical Resolve claims, which MDxHealth is disputing through the Medicare appeals process.
Q1 2026 revenue was $27.4 million as reported, or $23.9 million on a pro forma basis excluding Resolve, which management said represented 11% growth in the core prostate cancer business.
Pro forma operating loss widened to $7.9 million from $4.7 million a year ago, while pro forma net loss was $9.4 million, reflecting the added impact of the ExoDx acquisition.
Management reaffirmed its focus on prostate cancer diagnostics and raised 2026 revenue guidance for the core business to $110 million-$115 million, implying 20%-26% year-over-year growth.

MDxHealth Trading Down 49.5%

Shares of MDXH traded down $0.97 during midday trading on Thursday, reaching $0.98. 10,977,563 shares of the company were exchanged, compared to its average volume of 252,661. The stock has a 50-day moving average price of $2.47 and a 200-day moving average price of $3.25. The company has a market cap of $48.74 million, a price-to-earnings ratio of -1.47 and a beta of 1.60. MDxHealth has a 1-year low of $0.94 and a 1-year high of $5.33.

Key MDxHealth News

Here are the key news stories impacting MDxHealth this week:

Positive Sentiment: Lake Street Capital cut its price target to $5.00 from $9.00, but reiterated a buy rating, suggesting meaningful upside from the current share price despite the reduced target. Lake Street Capital price target cut
Positive Sentiment: BTIG Research also lowered its target to $4.00 from $7.00 while keeping a buy rating, indicating analysts still see recovery potential even after the earnings reset. BTIG Research price target cut
Neutral Sentiment: MDxHealth reported first-quarter 2026 results, including revenue of $23.9 million and adjusted EPS of -$0.19, which investors are parsing for signs of operating improvement. Q1 2026 earnings report
Negative Sentiment: The quarter missed Wall Street expectations on both profit and revenue, with EPS below estimates and sales well under consensus, reinforcing concerns about execution and growth momentum. Q1 2026 earnings miss
Negative Sentiment: Management’s FY2026 revenue guidance of $110 million to $115 million came in below the market’s expectation of about $122.6 million, adding pressure to the stock after the earnings release. FY2026 guidance
Negative Sentiment: William Blair downgraded MDxHealth from outperform to market perform, another sign that sentiment has cooled after the weak quarterly update. William Blair downgrade

Wall Street Analyst Weigh In

MDXH has been the topic of a number of research analyst reports. BTIG Research reduced their target price on MDxHealth from $7.00 to $4.00 and set a “buy” rating on the stock in a report on Thursday. Lake Street Capital reduced their target price on MDxHealth from $9.00 to $5.00 and set a “buy” rating on the stock in a report on Thursday. Weiss Ratings reiterated a “sell (d-)” rating on shares of MDxHealth in a report on Friday, March 27th. William Blair cut MDxHealth from an “outperform” rating to a “market perform” rating in a report on Thursday. Finally, TD Cowen reiterated a “buy” rating and issued a $1.50 target price (down from $7.00) on shares of MDxHealth in a report on Thursday. Four equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $4.63.

Get Our Latest Research Report on MDXH

Institutional Trading of MDxHealth

A number of hedge funds and other institutional investors have recently modified their holdings of MDXH. Kennedy Capital Management LLC purchased a new stake in shares of MDxHealth during the third quarter worth about $1,826,000. Marshall Wace LLP bought a new stake in MDxHealth in the fourth quarter valued at about $609,000. Panoramic Capital LLC bought a new position in shares of MDxHealth during the third quarter valued at approximately $721,000. 683 Capital Management LLC bought a new position in shares of MDxHealth during the fourth quarter valued at approximately $384,000. Finally, Mink Brook Asset Management LLC grew its holdings in shares of MDxHealth by 64.9% during the fourth quarter. Mink Brook Asset Management LLC now owns 263,420 shares of the company’s stock valued at $940,000 after purchasing an additional 103,686 shares during the last quarter.

MDxHealth Company Profile

(Get Free Report)

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.